OSE

NANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on Tedopi® (neoepitope-based cancer vaccine) in…

NANTES, France, Nov. 15, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)  presented the first positive preclinical efficacy data on its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type…

NANTES, France, Oct. 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that its Chief Scientific Officer Nicolas Poirier will present the latest preclinical progress on the bispecific…

NANTES, France, Oct. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)  announces that three abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 36th…

NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of Phase 3 clinical results of Tedopi® today at 13:30 CEST in a late-breaking oral presentation at the…

BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.Data from Phase 1 dose escalation indicate that…

Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the US…

PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have announced enrollment of the first…

NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial for CoVepiT, the…

This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs.This €10 million payment reinforces the Company’s financial…